<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131453</url>
  </required_header>
  <id_info>
    <org_study_id>CCNP520A2202J</org_study_id>
    <secondary_id>2016-002976-28</secondary_id>
    <nct_id>NCT03131453</nct_id>
  </id_info>
  <brief_title>A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease</brief_title>
  <acronym>GS2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banner Alzheimer's Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of CNP520 on cognition, global clinical&#xD;
      status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for&#xD;
      the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial was a randomized, double-blind, placebo-controlled, parallel group, adaptive&#xD;
      design with variable treatment duration planned in cognitively unimpaired participants aged&#xD;
      60 to 75 years, with at least one apolipoprotein E allele (APOE4), (homozygotes (HMs) or&#xD;
      heterozygotes (HTs)) and, if HTs, with evidence of elevated brain amyloid. The participants&#xD;
      were randomized to either CNP520 50 mg, CNP520 15 mg or placebo a 2:1:2 ratio and was&#xD;
      stratified based on amyloid status. The planned treatment period of 5 to 8 years was not&#xD;
      achieved due to early study termination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to safety issues.&#xD;
  </why_stopped>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Actual">March 26, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD))</measure>
    <time_frame>Baseline to last cognitive assessment performed (up to day 648)</time_frame>
    <description>Event was defined as the first confirmed diagnosis of MCI due to Alzheimer's disease (AD) or dementia due to AD (whichever occurred first) after adjudication by the progression adjudication committee (PAC) as triggered either by an investigator diagnosis or an increase in the Clinical Dementia Rating (CDR) global score. An event had to be confirmed by the PAC at two consecutive visits. In case no confirmed event was observed for a participant, the observation was censored, and the censoring date was defined as the last date where the diagnostic classification was assessed. The Study was terminated and only confirmed events collected up to the data cut-off point were counted. Due to the early termination of the study only a small number of events were observed and time-to-event could not be analyzed. Kaplan-Meyer (KM) estimates were provided to estimate probability that a subject would have an event prior to the specified visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score</measure>
    <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>APCC is a composite score derived from the specific scores from the Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE) and the Raven's Progressive Matrices. The APCC score is a weighted score with ranges from from 0 to 100 where higher scores correspond to better cognitive performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Score</measure>
    <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>The CDR was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated on a 5-point scale of functioning in six domains: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. The CDR global score ranged from zero to three, while the CDR-SOB was the sum of the ratings from the six domains, ranging from 0 to 18 with a minimum increment of 0.5. Higher scores indicated greater disease severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Total and Index Scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Repeatable Battery for the Assessment of Neurological Status (RBANS) is a clinical tool designed to detect and characterize the earliest neurocognitive changes associated with dementia. The RBANS generates age-adjusted index scores for five neurocognitive domains: Immediate Memory, Visuospatial/Constructional, Language, Attention and Delayed Memory, which are used to calculate a Total Scale Index score. Index scores and total score range from 40 to 160 and a higher score indicates better cognitive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Everyday Cognition Scale (ECog-Subject) Total Scores</measure>
    <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Everyday Cognition Scale (ECog-Informant) Total Scores</measure>
    <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Newly Occurring Safety MRI Abnormalities (ARIA-E, ARIA-H,White Matter Disease and Any Other MRI Abnormalities)</measure>
    <time_frame>Baseline up to study termination approximately 617 days</time_frame>
    <description>Safety MRI included sequences necessary for ascertainment of possible ARIA-E (Amyloid Related Imaging Abnormality-Edema), ARIA-H (Amyloid Related Imaging Abnormality- Hemorrhage, including superficial siderosis and microhemorrhages), assessment of recent infarcts and white matter integrity examination (White matter disease worsening) and a general assessment of brain abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Percent Change on Volume of Brain Regions</measure>
    <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Annualized % change from baseline in volume of specific brain regions of interest (ROIs): whole brain (WB), hippocampus (Hip), and lateral ventricles (LV). Annualized percentage change was calculated as (percentage per participant / time interval (in days)) x 365.25. Time interval (in days) was derived as date of current MRI assessment on study drug - date of baseline MRI assessment + 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Levels of Amyloid Beta 40 (Aβ40)</measure>
    <time_frame>Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 40 (Aβ40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Levels of Amyloid Beta 42 (Aβ42)</measure>
    <time_frame>Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 42 (Aβ42).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurofibrillary Tangle Burden as Measured by Standardized Uptake Ratio (SUVR) of PET Scans With Tau Radiotracer (Where Available)</measure>
    <time_frame>Baseline to Months 24 and 60</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Amyloid Deposition as Measured by Standardized Uptake Ratio (SUVR) of Positron Emission Tomography (PET) Scan With Amyloid Radiotracer</measure>
    <time_frame>Baseline to Months 24 and 60</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Levels of Total Tau and Phosphorylated Tau</measure>
    <time_frame>Baseline to Last on-treatment (Day 547) Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): total tau protein and phosphorylated tau protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Neurofilaments</measure>
    <time_frame>Baseline to Week 26, baseline to Last on-treatment (Day 547) Baseline to Last off-treatment (Day 648)</time_frame>
    <description>Alzheimer's Disease-related biomarkers analyzed in blood serum: light chain neurofilaments (NfL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Suicidal Ideation or Behavior Events</measure>
    <time_frame>Baseline up to study termination approximately 617 days</time_frame>
    <description>Prospective suicidality assessment was performed with the use of Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire using a detailed branched logic algorithm evaluating participant's suicidality ideation and behavior. Answer &quot;yes&quot; on item 4 or 5 of the Suicidal Ideation section or &quot;yes&quot; on any item of the Suicidal Behavior section was considered positive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1145</enrollment>
  <condition>Alzheimers Disease</condition>
  <arm_group>
    <arm_group_label>CNP520 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg capsule taken orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNP520 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg capsule taken orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNP520 50mg</intervention_name>
    <description>50 mg capsule</description>
    <arm_group_label>CNP520 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNP520 15mg</intervention_name>
    <description>15 mg capsule</description>
    <arm_group_label>CNP520 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Matching placebo for 15 and 50 mg capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  consent to receive disclosure of their risk estimates to develop clinical symptoms of&#xD;
             AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain&#xD;
             amyloid.&#xD;
&#xD;
          -  Male or female, age 60 to 75 years inclusive. Females must be considered&#xD;
             post-menopausal and not of child bearing potential&#xD;
&#xD;
          -  Cognitively unimpaired as evaluated by memory tests performed at screening.&#xD;
&#xD;
          -  Participant's willingness to have a study partner.&#xD;
&#xD;
          -  Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as&#xD;
             measured by CSF Abeta or amyloid PET imaging).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disability that could have prevented the participants from completing all study&#xD;
             requirements. -&#xD;
&#xD;
          -  Current medical or neurological condition that could have impacted cognition or&#xD;
             performance on cognitive assessments.&#xD;
&#xD;
          -  Advanced, severe progressive or unstable disease that could have interfered with the&#xD;
             safety, tolerability and study assessments, or put the participant at special risk.&#xD;
&#xD;
          -  History of malignancy of any organ system, treated or untreated, within the past 60&#xD;
             months.&#xD;
&#xD;
          -  Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.&#xD;
             memantine).&#xD;
&#xD;
          -  Contraindication or intolerance to MRI.&#xD;
&#xD;
          -  Brain MRI results showing findings unrelated to AD that, in the opinion of the&#xD;
             Investigator might be a leading cause to future cognitive decline, could have posed a&#xD;
             risk to the participant, or could have prevented a satisfactory MRI assessment for&#xD;
             safety monitoring.&#xD;
&#xD;
          -  Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.&#xD;
&#xD;
          -  A positive drug screen at Screening, if, in the Investigator's opinion, was is due to&#xD;
             drug abuse.&#xD;
&#xD;
          -  Significantly abnormal laboratory results at Screening, not as a result of a temporary&#xD;
             condition.&#xD;
&#xD;
          -  Current clinically significant ECG findings.&#xD;
&#xD;
          -  Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,&#xD;
             vitiligo) or active / history of chronic urticaria in the past year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute, 901 East Willetta Street</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research Inc, 3151 Airway Avenue T 3</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Res, 2515 McCabe Way</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute, 25043 Narbonne Avenue</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sebastopol</city>
        <state>California</state>
        <zip>95472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain Neurological Research, 350 Market Street, Suite 316</name>
      <address>
        <city>Basalt</city>
        <state>Colorado</state>
        <zip>81621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Neurological, 2312 North Nevada Avenue, Suite 100</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Neurological Clinic, 950 E Harvard Ave</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, One Church Street, Suite 600</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462-6608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Laboratories</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research, Inc., 800 NW 17th Avenue</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research and Treatment Center, 5065 State Road 7, Suite 102</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research, 2300 Maitland center, Pkwy Ste 230</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center, 11880 SW 40 St., Suite 405</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami-Dade Medical Research, 8955 SW 87 CT, Suite 112</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC,100 West Gore Street, Suite 202</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute, Inc., 2040 Whitfield Avenue</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience, 2230 Liliha st 104</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, 2950 E Magic View Dr, Suite 182</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Neuroscience, 800 Biesterfield Rd, Neuroscience Institute Brock</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute, 28595 Orchard Lake Road, Suite 301</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, 415 South 28th Avenue</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198 7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Long Branch</city>
        <state>New Jersey</state>
        <zip>07764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience, 101 Hospital Loop ne, 209 209</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, Room 226</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ANI Neurology, PLLC dba Alzhe, 7809 Sardis Road</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulsa Clinical Research LLC, 1705 E 19th ST., STE 406/408</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network, 2701 NW Vaughn St, Suite 350</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital, 345 Blackstone Blvd.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper Hospital, 316 Calhoun Street 5th Floor</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scota</state>
        <zip>B4N 4K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program, 1 Valleybrook Drive Suite 400</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T 8J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>838 0456</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangdong</city>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <state>Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>PARIS Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogi</city>
        <zip>IS-201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milan</city>
        <zip>20112</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tōon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>814 0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita city</city>
        <state>Osaka</state>
        <zip>565 0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo ku</city>
        <state>Tokyo</state>
        <zip>113 8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba</city>
        <zip>260 8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi Do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Mexico CP</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Bosch</city>
        <state>Noord Brabant</state>
        <zip>5223 LA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 GN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torres Vedras</city>
        <state>Lisbon</state>
        <zip>2560-280</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000 075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matosinhos</city>
        <zip>4454 513</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inspira Clinical Research, Ave Hostos 405</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosebank</city>
        <state>Johannesburg</state>
        <zip>2132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>George</city>
        <state>ZAF</state>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Donostia-San Sebastian</city>
        <zip>20009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <state>CH</state>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geneve</city>
        <zip>1227</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaoshiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>GBR</state>
        <zip>W12 7RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU27YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Avon</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B16 8QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W1G 9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Iceland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.generationprogram.com</url>
    <description>Generation Program Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <results_first_submitted>March 25, 2021</results_first_submitted>
  <results_first_submitted_qc>August 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2021</results_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Placebo controlled</keyword>
  <keyword>APOE4 carriers</keyword>
  <keyword>Homozygotes</keyword>
  <keyword>Heterozygotes</keyword>
  <keyword>Brain Amyloid</keyword>
  <keyword>Aβ lowering</keyword>
  <keyword>BACE-1 inhibitor</keyword>
  <keyword>CNP520</keyword>
  <keyword>elderly</keyword>
  <keyword>preclinical Alzheimers disease</keyword>
  <keyword>Alzheimers Disease</keyword>
  <keyword>Prevention</keyword>
  <keyword>Unimpaired cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CNP520</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03131453/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03131453/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>8970 participants were screened</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CNP520 50 mg</title>
          <description>50 mg capsule taken orally once daily</description>
        </group>
        <group group_id="P2">
          <title>CNP520 15 mg</title>
          <description>15 mg capsule taken orally once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="456"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patient Misrandomized</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="456"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="438"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient was misrandomized and not included in the CNP520 50mg arm</population>
      <group_list>
        <group group_id="B1">
          <title>CNP520 50 mg</title>
          <description>50 mg capsule taken orally once daily</description>
        </group>
        <group group_id="B2">
          <title>CNP520 15 mg</title>
          <description>15 mg capsule taken orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="455"/>
            <count group_id="B2" value="233"/>
            <count group_id="B3" value="456"/>
            <count group_id="B4" value="1144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="288"/>
                    <measurement group_id="B4" value="720"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="416"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="422"/>
                    <measurement group_id="B4" value="1051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline cognitive scale assessment</title>
          <description>APCC(API Preclinical Composite Cognitive Battery) is a composite score derived from RBANS(Repeatable Battery for Assessment of Neurological Status), MMSE(Mini-Mental State Examination) and the Raven's Progressive Matrices; scores: 0-100/higher scores=better cognitive performance. RBANS is a tool to detect/characterize neurocognitive dementia changes in 5 neurocognitive domains; scores: 40-160/higher scores=better cognitive functioning. Clinical Dementia Rating Sum of Boxes(CDR-SOB) measures cognition+functioning in 6 domains; scores: 0-18/higher scores indicate greater disease severity</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>APCC score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.6" spread="6.68"/>
                    <measurement group_id="B2" value="75.8" spread="6.81"/>
                    <measurement group_id="B3" value="74.9" spread="7.16"/>
                    <measurement group_id="B4" value="75.0" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.5" spread="11.96"/>
                    <measurement group_id="B2" value="102.0" spread="12.09"/>
                    <measurement group_id="B3" value="100.7" spread="12.42"/>
                    <measurement group_id="B4" value="100.9" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDR-SOB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.19" spread="0.389"/>
                    <measurement group_id="B2" value="0.16" spread="0.358"/>
                    <measurement group_id="B3" value="0.14" spread="0.358"/>
                    <measurement group_id="B4" value="0.16" spread="0.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD))</title>
        <description>Event was defined as the first confirmed diagnosis of MCI due to Alzheimer's disease (AD) or dementia due to AD (whichever occurred first) after adjudication by the progression adjudication committee (PAC) as triggered either by an investigator diagnosis or an increase in the Clinical Dementia Rating (CDR) global score. An event had to be confirmed by the PAC at two consecutive visits. In case no confirmed event was observed for a participant, the observation was censored, and the censoring date was defined as the last date where the diagnostic classification was assessed. The Study was terminated and only confirmed events collected up to the data cut-off point were counted. Due to the early termination of the study only a small number of events were observed and time-to-event could not be analyzed. Kaplan-Meyer (KM) estimates were provided to estimate probability that a subject would have an event prior to the specified visit.</description>
        <time_frame>Baseline to last cognitive assessment performed (up to day 648)</time_frame>
        <population>Safety analysis set; n=number of participants at risk to experience an event at the time-point</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD))</title>
          <description>Event was defined as the first confirmed diagnosis of MCI due to Alzheimer's disease (AD) or dementia due to AD (whichever occurred first) after adjudication by the progression adjudication committee (PAC) as triggered either by an investigator diagnosis or an increase in the Clinical Dementia Rating (CDR) global score. An event had to be confirmed by the PAC at two consecutive visits. In case no confirmed event was observed for a participant, the observation was censored, and the censoring date was defined as the last date where the diagnostic classification was assessed. The Study was terminated and only confirmed events collected up to the data cut-off point were counted. Due to the early termination of the study only a small number of events were observed and time-to-event could not be analyzed. Kaplan-Meyer (KM) estimates were provided to estimate probability that a subject would have an event prior to the specified visit.</description>
          <population>Safety analysis set; n=number of participants at risk to experience an event at the time-point</population>
          <units>probability of an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 n=232,123,250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.96" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.97" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 n=52,24,57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.94" upper_limit="0.99"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.92" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.96" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 n=6,2,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.94" upper_limit="0.99"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.92" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.88" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score</title>
        <description>APCC is a composite score derived from the specific scores from the Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE) and the Raven's Progressive Matrices. The APCC score is a weighted score with ranges from from 0 to 100 where higher scores correspond to better cognitive performance.</description>
        <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score</title>
          <description>APCC is a composite score derived from the specific scores from the Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE) and the Raven's Progressive Matrices. The APCC score is a weighted score with ranges from from 0 to 100 where higher scores correspond to better cognitive performance.</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>Total scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 n=160,79,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="5.20"/>
                    <measurement group_id="O2" value="-2.9" spread="5.00"/>
                    <measurement group_id="O3" value="-1.7" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last on-treatment n=269,144,275</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="4.88"/>
                    <measurement group_id="O2" value="-0.8" spread="4.67"/>
                    <measurement group_id="O3" value="-1.3" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last off-treatment n=255,124,260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="124"/>
                    <count group_id="O3" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="4.56"/>
                    <measurement group_id="O2" value="-0.8" spread="4.38"/>
                    <measurement group_id="O3" value="-0.8" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Score</title>
        <description>The CDR was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated on a 5-point scale of functioning in six domains: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. The CDR global score ranged from zero to three, while the CDR-SOB was the sum of the ratings from the six domains, ranging from 0 to 18 with a minimum increment of 0.5. Higher scores indicated greater disease severity</description>
        <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Score</title>
          <description>The CDR was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated on a 5-point scale of functioning in six domains: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. The CDR global score ranged from zero to three, while the CDR-SOB was the sum of the ratings from the six domains, ranging from 0 to 18 with a minimum increment of 0.5. Higher scores indicated greater disease severity</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 n=160,78,160</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.606"/>
                    <measurement group_id="O2" value="0.20" spread="0.451"/>
                    <measurement group_id="O3" value="0.08" spread="0.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last on-treatment n=265,144,267</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.557"/>
                    <measurement group_id="O2" value="0.08" spread="0.449"/>
                    <measurement group_id="O3" value="0.10" spread="0.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last off-treatment n=254,117,256</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.525"/>
                    <measurement group_id="O2" value="0.07" spread="0.401"/>
                    <measurement group_id="O3" value="0.10" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Total and Index Scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</title>
        <description>Repeatable Battery for the Assessment of Neurological Status (RBANS) is a clinical tool designed to detect and characterize the earliest neurocognitive changes associated with dementia. The RBANS generates age-adjusted index scores for five neurocognitive domains: Immediate Memory, Visuospatial/Constructional, Language, Attention and Delayed Memory, which are used to calculate a Total Scale Index score. Index scores and total score range from 40 to 160 and a higher score indicates better cognitive functioning.</description>
        <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Total and Index Scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</title>
          <description>Repeatable Battery for the Assessment of Neurological Status (RBANS) is a clinical tool designed to detect and characterize the earliest neurocognitive changes associated with dementia. The RBANS generates age-adjusted index scores for five neurocognitive domains: Immediate Memory, Visuospatial/Constructional, Language, Attention and Delayed Memory, which are used to calculate a Total Scale Index score. Index scores and total score range from 40 to 160 and a higher score indicates better cognitive functioning.</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Week 26 n=162,81,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="8.54"/>
                    <measurement group_id="O2" value="-6.3" spread="8.58"/>
                    <measurement group_id="O3" value="-3.4" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Last on-treatment n=356,183,353</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="356"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="8.66"/>
                    <measurement group_id="O2" value="-3.5" spread="8.87"/>
                    <measurement group_id="O3" value="-0.5" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Last off-treatment n=259,125,265</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="8.12"/>
                    <measurement group_id="O2" value="-2.4" spread="9.55"/>
                    <measurement group_id="O3" value="-1.9" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate memory - Week 26 n=162,81,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="11.85"/>
                    <measurement group_id="O2" value="-9.7" spread="12.10"/>
                    <measurement group_id="O3" value="-5.2" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate memory - Last on-treatment n=347,183,353</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="13.01"/>
                    <measurement group_id="O2" value="-4.0" spread="13.54"/>
                    <measurement group_id="O3" value="-1.1" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate memory - Last off-treatment n=259,125,266</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="12.50"/>
                    <measurement group_id="O2" value="-4.8" spread="13.52"/>
                    <measurement group_id="O3" value="-3.0" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visuospatial Week 26 n=162,81,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="15.11"/>
                    <measurement group_id="O2" value="-5.4" spread="15.51"/>
                    <measurement group_id="O3" value="-2.6" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visuospatial Last on-treatment n=347,183,353</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="14.90"/>
                    <measurement group_id="O2" value="-3.8" spread="15.14"/>
                    <measurement group_id="O3" value="-1.2" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visuospatial Last off-treatment n=259,125,266</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="14.87"/>
                    <measurement group_id="O2" value="-0.7" spread="14.37"/>
                    <measurement group_id="O3" value="-1.2" spread="14.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Language Week 26 n=162,81,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="11.48"/>
                    <measurement group_id="O2" value="-1.8" spread="11.05"/>
                    <measurement group_id="O3" value="-3.1" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Language Last on-treatment n=347,183,353</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="11.95"/>
                    <measurement group_id="O2" value="-1.7" spread="11.69"/>
                    <measurement group_id="O3" value="-1.3" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Language Last off-treatment n=259,125,265</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="10.93"/>
                    <measurement group_id="O2" value="-2.0" spread="12.68"/>
                    <measurement group_id="O3" value="-3.4" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention Week 26 n=162,81,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="11.19"/>
                    <measurement group_id="O2" value="-0.1" spread="10.37"/>
                    <measurement group_id="O3" value="0.1" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention Last on-treatment n=347,183,353</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="11.30"/>
                    <measurement group_id="O2" value="0.0" spread="10.68"/>
                    <measurement group_id="O3" value="0.7" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention Last off-treatment n=259,125,265</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="11.59"/>
                    <measurement group_id="O2" value="1.7" spread="10.65"/>
                    <measurement group_id="O3" value="1.1" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed memory - Week 26 n=162,81,162</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="11.54"/>
                    <measurement group_id="O2" value="-5.0" spread="11.68"/>
                    <measurement group_id="O3" value="-2.1" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed memory - Last on-treatment n=346,183,353</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="346"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="11.58"/>
                    <measurement group_id="O2" value="-2.8" spread="10.56"/>
                    <measurement group_id="O3" value="0.8" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed memory - Last off-treatment n=259,125,265</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="10.91"/>
                    <measurement group_id="O2" value="-2.5" spread="10.34"/>
                    <measurement group_id="O3" value="-0.5" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Everyday Cognition Scale (ECog-Subject) Total Scores</title>
        <description>Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function.</description>
        <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Everyday Cognition Scale (ECog-Subject) Total Scores</title>
          <description>Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function.</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>Total scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 n=155,78,157</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="7.90"/>
                    <measurement group_id="O2" value="0.2" spread="5.52"/>
                    <measurement group_id="O3" value="0.5" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last on-treatment n=266,143,268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="8.03"/>
                    <measurement group_id="O2" value="0.4" spread="5.62"/>
                    <measurement group_id="O3" value="0.7" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last off-treatment n=249,122,255</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="6.49"/>
                    <measurement group_id="O2" value="0.0" spread="7.02"/>
                    <measurement group_id="O3" value="0.1" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Everyday Cognition Scale (ECog-Informant) Total Scores</title>
        <description>Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function.</description>
        <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Everyday Cognition Scale (ECog-Informant) Total Scores</title>
          <description>Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function.</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>Total scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 n=153,76,153</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.55"/>
                    <measurement group_id="O2" value="1.7" spread="7.77"/>
                    <measurement group_id="O3" value="-1.2" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last on-treatment n=252,138,255</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="7.58"/>
                    <measurement group_id="O2" value="0.7" spread="8.49"/>
                    <measurement group_id="O3" value="0.2" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last off-treatment n=223,113,239</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="6.97"/>
                    <measurement group_id="O2" value="0.0" spread="6.74"/>
                    <measurement group_id="O3" value="1.2" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Newly Occurring Safety MRI Abnormalities (ARIA-E, ARIA-H,White Matter Disease and Any Other MRI Abnormalities)</title>
        <description>Safety MRI included sequences necessary for ascertainment of possible ARIA-E (Amyloid Related Imaging Abnormality-Edema), ARIA-H (Amyloid Related Imaging Abnormality- Hemorrhage, including superficial siderosis and microhemorrhages), assessment of recent infarcts and white matter integrity examination (White matter disease worsening) and a general assessment of brain abnormalities.</description>
        <time_frame>Baseline up to study termination approximately 617 days</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Newly Occurring Safety MRI Abnormalities (ARIA-E, ARIA-H,White Matter Disease and Any Other MRI Abnormalities)</title>
          <description>Safety MRI included sequences necessary for ascertainment of possible ARIA-E (Amyloid Related Imaging Abnormality-Edema), ARIA-H (Amyloid Related Imaging Abnormality- Hemorrhage, including superficial siderosis and microhemorrhages), assessment of recent infarcts and white matter integrity examination (White matter disease worsening) and a general assessment of brain abnormalities.</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence of ARIA-H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Questionable presence of ARIA-E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White matter disease worsening: 1-3 increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White matter disease worsening: 4- - &gt;8 increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White matter disease worsening &gt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other MRI abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Percent Change on Volume of Brain Regions</title>
        <description>Annualized % change from baseline in volume of specific brain regions of interest (ROIs): whole brain (WB), hippocampus (Hip), and lateral ventricles (LV). Annualized percentage change was calculated as (percentage per participant / time interval (in days)) x 365.25. Time interval (in days) was derived as date of current MRI assessment on study drug - date of baseline MRI assessment + 1.</description>
        <time_frame>Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Percent Change on Volume of Brain Regions</title>
          <description>Annualized % change from baseline in volume of specific brain regions of interest (ROIs): whole brain (WB), hippocampus (Hip), and lateral ventricles (LV). Annualized percentage change was calculated as (percentage per participant / time interval (in days)) x 365.25. Time interval (in days) was derived as date of current MRI assessment on study drug - date of baseline MRI assessment + 1.</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>Percentage of volume change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WB Week 26 n=169,83,169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1016" spread="1.03196"/>
                    <measurement group_id="O2" value="-0.9348" spread="0.85477"/>
                    <measurement group_id="O3" value="-0.5552" spread="1.21385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WB Last on-treatment n=179,85,182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0427" spread="0.93751"/>
                    <measurement group_id="O2" value="-0.9205" spread="0.75633"/>
                    <measurement group_id="O3" value="-0.5378" spread="1.09542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WB Last off-treatment n=72,44,81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6984" spread="0.73644"/>
                    <measurement group_id="O2" value="-0.9188" spread="0.94516"/>
                    <measurement group_id="O3" value="-0.5811" spread="0.75412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip Week 26 n=169,83,169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0993" spread="2.77159"/>
                    <measurement group_id="O2" value="-1.9100" spread="2.31406"/>
                    <measurement group_id="O3" value="-1.2113" spread="2.71764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip Last on-treatment n=179,85,182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0052" spread="2.65898"/>
                    <measurement group_id="O2" value="-1.7909" spread="2.06883"/>
                    <measurement group_id="O3" value="-1.1628" spread="2.56183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip Last off-treatment n=72,44,81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3755" spread="1.90613"/>
                    <measurement group_id="O2" value="-1.2522" spread="2.23213"/>
                    <measurement group_id="O3" value="-1.1929" spread="1.81333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Week 26 n=169,83,169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4388" spread="5.91870"/>
                    <measurement group_id="O2" value="5.3457" spread="4.67788"/>
                    <measurement group_id="O3" value="3.5415" spread="4.75268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Last on-treatment n=179,85,182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0974" spread="5.31542"/>
                    <measurement group_id="O2" value="5.0822" spread="3.88165"/>
                    <measurement group_id="O3" value="3.4582" spread="4.35888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Last off-treatment n=72,44,81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0014" spread="4.29087"/>
                    <measurement group_id="O2" value="3.9355" spread="5.17657"/>
                    <measurement group_id="O3" value="3.3851" spread="3.38576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Levels of Amyloid Beta 40 (Aβ40)</title>
        <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 40 (Aβ40)</description>
        <time_frame>Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Levels of Amyloid Beta 40 (Aβ40)</title>
          <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 40 (Aβ40)</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AB40 Last on-treatment n=1,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.320"/>
                    <measurement group_id="O3" value="-0.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AB40 Last off-treatment n=16,5,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.492" spread="1.9263"/>
                    <measurement group_id="O2" value="0.804" spread="1.9220"/>
                    <measurement group_id="O3" value="-1.172" spread="1.7408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Levels of Amyloid Beta 42 (Aβ42)</title>
        <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 42 (Aβ42).</description>
        <time_frame>Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Levels of Amyloid Beta 42 (Aβ42)</title>
          <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 42 (Aβ42).</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AB42 Last on-treatment n=1,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-366.200"/>
                    <measurement group_id="O3" value="-61.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AB42 Last off-treatment n=16,5,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.431" spread="74.5595"/>
                    <measurement group_id="O2" value="-68.660" spread="62.8505"/>
                    <measurement group_id="O3" value="21.246" spread="104.3395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurofibrillary Tangle Burden as Measured by Standardized Uptake Ratio (SUVR) of PET Scans With Tau Radiotracer (Where Available)</title>
        <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
        <time_frame>Baseline to Months 24 and 60</time_frame>
        <population>No available data since no post-baseline (month 24 and 60) PET scan could be obtained due to the early termination of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neurofibrillary Tangle Burden as Measured by Standardized Uptake Ratio (SUVR) of PET Scans With Tau Radiotracer (Where Available)</title>
          <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
          <population>No available data since no post-baseline (month 24 and 60) PET scan could be obtained due to the early termination of the trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Amyloid Deposition as Measured by Standardized Uptake Ratio (SUVR) of Positron Emission Tomography (PET) Scan With Amyloid Radiotracer</title>
        <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
        <time_frame>Baseline to Months 24 and 60</time_frame>
        <population>No available data since no post-baseline (month 24 and 60) PET scan could be obtained due to the early termination of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Amyloid Deposition as Measured by Standardized Uptake Ratio (SUVR) of Positron Emission Tomography (PET) Scan With Amyloid Radiotracer</title>
          <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
          <population>No available data since no post-baseline (month 24 and 60) PET scan could be obtained due to the early termination of the trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Levels of Total Tau and Phosphorylated Tau</title>
        <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): total tau protein and phosphorylated tau protein levels</description>
        <time_frame>Baseline to Last on-treatment (Day 547) Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Levels of Total Tau and Phosphorylated Tau</title>
          <description>Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): total tau protein and phosphorylated tau protein levels</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total tau - Last on-treatment n=1,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.000"/>
                    <measurement group_id="O3" value="-12.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total tau - Last off-treatment n=16,5,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.119" spread="28.6218"/>
                    <measurement group_id="O2" value="-3.320" spread="21.1548"/>
                    <measurement group_id="O3" value="-3.238" spread="23.4442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorylated tau - Last on-treatment n=1,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.360"/>
                    <measurement group_id="O3" value="-0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorylated tau - Last off-treatment n=16,5,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.849" spread="2.3397"/>
                    <measurement group_id="O2" value="-0.852" spread="2.7005"/>
                    <measurement group_id="O3" value="0.065" spread="1.3032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Neurofilaments</title>
        <description>Alzheimer's Disease-related biomarkers analyzed in blood serum: light chain neurofilaments (NfL)</description>
        <time_frame>Baseline to Week 26, baseline to Last on-treatment (Day 547) Baseline to Last off-treatment (Day 648)</time_frame>
        <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Neurofilaments</title>
          <description>Alzheimer's Disease-related biomarkers analyzed in blood serum: light chain neurofilaments (NfL)</description>
          <population>Safety analysis set - only participants with a value at both Baseline and that visit are included. Last on-treatment is the last assessment before or at last day on study drug + 31 days. Last off-treatment is the last assessment after last day on study drug + 31 days.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 n=33,17,38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.622" spread="4.5576"/>
                    <measurement group_id="O2" value="0.901" spread="4.6732"/>
                    <measurement group_id="O3" value="-5.731" spread="40.9042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last on-treatment n=33,15,40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.932" spread="4.2494"/>
                    <measurement group_id="O2" value="0.041" spread="3.4144"/>
                    <measurement group_id="O3" value="-5.771" spread="39.8254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last off-treatment n=5,2,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.764" spread="3.0981"/>
                    <measurement group_id="O2" value="7.350" spread="9.5884"/>
                    <measurement group_id="O3" value="3.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Suicidal Ideation or Behavior Events</title>
        <description>Prospective suicidality assessment was performed with the use of Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire using a detailed branched logic algorithm evaluating participant's suicidality ideation and behavior. Answer &quot;yes&quot; on item 4 or 5 of the Suicidal Ideation section or &quot;yes&quot; on any item of the Suicidal Behavior section was considered positive.</description>
        <time_frame>Baseline up to study termination approximately 617 days</time_frame>
        <population>Safety analysis set which includes only participants with events</population>
        <group_list>
          <group group_id="O1">
            <title>CNP520 50 mg</title>
            <description>50 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O2">
            <title>CNP520 15 mg</title>
            <description>15 mg capsule taken orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Suicidal Ideation or Behavior Events</title>
          <description>Prospective suicidality assessment was performed with the use of Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire using a detailed branched logic algorithm evaluating participant's suicidality ideation and behavior. Answer &quot;yes&quot; on item 4 or 5 of the Suicidal Ideation section or &quot;yes&quot; on any item of the Suicidal Behavior section was considered positive.</description>
          <population>Safety analysis set which includes only participants with events</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any suicidal ideation n=13,3,9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any suicidal behavior n=1,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from first dose of study treatment until end of study treatment plus 31 days of washout period for a maximum duration of 617 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CNP520 50 mg</title>
          <description>50 mg capsule taken orally once daily</description>
        </group>
        <group group_id="E2">
          <title>CNP520 15 mg</title>
          <description>15 mg capsule taken orally once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebo to 15 and 50 mg CNP520 taken orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Serum ferritin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Chordoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="455"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="456"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated due to safety issues.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+ 1 862 778 8300</phone>
      <email>Novartis.email@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

